HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wellness Market News: Nuritas-Pharmavite Peptides, Abbott Nutriton, Brain Armor, Trade Group Notes

Executive Summary

Pharmavite tests bioactive peptides with Nuritas' AI platform; NPA questions FDA proposal to share data collected from US firms; NFL great Randy White promotes Brain Armor supplements; Abbott Nutrition sales up 4.4% for 2018; ONHA targets expanding omega-3 testing among consumers; CRN's Mister, Sidley's Bass co-chair regulatory conference; and 'Hero for the Planet' Plotkin speaks at AHPA meeting.

You may also be interested in...



Beauty Market News: China Cosmetics Regulations Modernized, Florida Stops Local Oxybenzone Bans, More

L’Oreal acquires Thayers Natural Remedies; Unilever, L’Oreal remove ‘whitening,’ ‘fair’ from labels; China finalizes modernization of cosmetics regulations; and Florida governor signs law preventing local bans on oxybenzone.

Compounded Hormone Therapies Lack Evidence Of Safety And Effectiveness, Say National Academies

The US Food and Drug Administration should require that outsourcing facilities collect bioavailability data for compounded bioidentical hormone replacement therapy products, while compounding pharmacies should be required to report adverse events to state pharmacy boards and the FDA. Such actions would help resolve some of the safety concerns for these products, says a 1 July report from the National Academy of Sciences, Engineering and Medicine.

Biogen/Eisai Hit ‘Send’ On High Stakes BLA For Aducanumab In Alzheimer’s Disease

Some analysts see a 50-50 chance of US FDA approval despite the controversial dataset for the anti-amyloid antibody, but at least one expects an eventual CRL requesting a third Phase III trial.

Topics

Related Companies

UsernamePublicRestriction

Register

LL025498

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel